Huabang pharmaceutical, a skin drug, tazarotene, betamethasone cream, enters the site for inspection

According to the public information, tazarotene betamethasone cream is a compound preparation of tazarotene and betamethasone, which is mainly used for the treatment of psoriasis It is developed by Huabang Yingtai, and has not been declared by other manufacturers After being approved, it will become an exclusive product In 2013, the market scale of psoriasis in sample hospitals was 84.86 million yuan, and Huabang pharmaceutical accounted for 10% of the market share The rest was occupied by foreign enterprises According to Shenyin Wanguo Research Report, the market sales of tazarotene betamethasone cream is expected to reach 100-200 million yuan It is worth noting that Huabang pharmaceutical's tazarotene betamethasone cream has been listed in the 76 major special varieties released by CDE As early as 2012, the product was also included in the list of 100 key products of Chongqing pharmaceutical industry, with a total investment of 8 billion yuan According to the information of the State Administration of drug control, the company is reporting more than 20 varieties of clinical and subsequent research and development stages, such as the production of three new drugs, palonisetron hydrochloride, linezolid and halomisone, and the clinical application of three new drugs, oloprazin hydrochloride nasal spray and Luo Fu's tablets, of which Moxifloxacin Hydrochloride Tablets and methylprednisolone succinate are used for injection Sodium and tazarotene betamethasone cream are expected to be approved in 2014 Founded in September 1994, Huabang Pharmaceutical Co., Ltd is a pharmaceutical enterprise mainly engaged in the R & D, production and sales of skin and tuberculosis drugs It is the core business medicine business department of Huabang Yingtai group (Shenzhen code 002004), a listed company Its headquarter is located next to the core happiness square of Liangjiang New District, Chongqing, covering an area of 260 mu Preparations and API products are sold to domestic and overseas markets, and have been the leading position in clinical dermatology in China for many years.